Precision Health AI and Vector Oncology Partner to Analyze, Build and Curate the Largest/Best Real World Cancer Data Set, to Build Groundbreaking AI-Enhanced Solutions

Pharma, Payers and Providers Can Now Preview the Power of SymphonyAI Companies’ Definitive Real World Oncology Data Set & Leading AI Oncology Solutions at ASCO 2018

NEW YORK (PRWEB) May 29, 2018

Precision Health AI (PH.AI), an oncology-focused AI solutions platform, today announced a partnership with Vector Oncology, a leader in design and delivery of healthcare-based oncology research and data analytics. The PH.AI partnership with ASCO/CancerlinQ, now paired with Vector Oncology’s world-class curation team, delivers the definitive database of real world cancer data -- to the benefit of the entire industry.

“It’s a waste that consumer apps and media targeting benefit from AI, but lifesaving pattern recognition and other tech-enhanced solutions for cancer diagnostics and treatment are hindered by the quality and organization of data,” said Romesh Wadhwani, founder and CEO of SymphonyAI, the parent company under which PH.AI and Vector Oncology operate. “We now put the power of CancerlinQ data -- enhanced with both descriptive and prescriptive AI metadata and Vector Oncology’s proprietary data -- to work for the benefit of the industry and the people it serves.”

Vector Oncology already serves 15 top pharmaceutical companies, and both designs and executes retrospective and multi-year hybrid studies to enroll targeted cohorts of patients in active treatment. The result delivers real-time, clinical research quality, real world evidence insights on treatment patterns, comparative effectiveness, health outcomes, and economics.

“Vector Oncology brings comprehensive existing data -- including retrospective and multi-year hybrid studies -- and a world-class curation team comprised of oncology nurse abstractors and exclusive curators,” said Brigham Hyde, PhD, Chief Executive Officer of Precision Health AI. “The richness this provides to our Eureka Health Oncology platform can’t be overstated.”

The EurekaHealth(™) oncology platform provides practical AI applications for real oncology use cases. The technology uses mass amounts of EMR and other data -- now including what Vector Oncology delivers -- to give insight to pharmaceutical companies and physicians about certain conditions. The platform is designed to help researchers and clinicians design targeted therapies, shape clinical trials, and determine what therapies offer the greatest patient benefits.

“Being able to conduct prospective, retrospective and hybrid studies based on real world evidence -- with the enormous dataset and incredible precision health-oriented solutions from PH.AI -- will further accelerate drug development, labeling and registration,” said Michael Choukas, CEO of Vector Oncology. “Our Health Economics and Outcomes Research (HEOR) offerings are significantly enhanced with this partnership.”

The partnership -- with both companies under the SymphonyAI parent -- will create a level of depth, breadth, and accuracy to existing research and data solutions that will ultimately demonstrate the real action-oriented effectiveness, safety, and value of oncology therapeutics.

Executives from PH.AI, SymphonyAI and Vector Oncology will be at ASCO Booth 25109, meeting with pharmaceutical companies.

About Precision Health AI
Precision Health AI is developing the leading artificial intelligence (AI) platform for oncology built on the largest longitudinal clinical oncology dataset to enable the practice of precision medicine for better cancer patient care, getting the right treatment to the right patient at the right time. Insights from Precision Health AI will accelerate cancer-related drug development, trials and real-world evidence for the benefit of the cancer care ecosystem of oncologists, pharmaceutical companies, payers and patients. To learn more, visit http://www.precisionhealth.ai.

About Vector Oncology
Vector Oncology is a leader in the design and delivery of care based oncology research and data analytics. Utilizing our comprehensive Oncology Data Warehouse and proprietary Patient Care Monitor (PCM) patient engagement and outcomes platform, our experienced project teams, medical experts and health economics and outcomes scientists design and deliver high-quality projects generating real world evidence and insight. With some of the most experienced medical, scientific, operational, and executive teams in late stage research, Vector Oncology is uniquely positioned to meet the demand to demonstrate product value in terms of economic impact, clinical effectiveness and tolerability, and patient reported outcomes (PRO). For more information, please visit http://www.vectoroncology.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2018/05/prweb15520773.htm